PTA-News: Marinomed Biotech AG: Marinomed announces change to supervisory board

Friday, 30. October 2020 09:00

Business news for the stock market

Korneuburg (pta009/30.10.2020/09:00) - 30 October 2020

* Karl Lankmayr to resign from the supervisory board at the end of October

Marinomed Biotech AG, a globally operating biopharmaceutical company based in Vienna, has announced that Karl Lankmayr will resign from his post as a member of the supervisory board on 31 October 2020. The company plans to appoint his successor at the next AGM.

Simon Nebel, chair of the supervisory board at Marinomed, commented on Mr Lankmayr's departure: "On behalf of the supervisory board, I would like to thank Karl Lankmayr for the substantial contribution he has made during his tenure. Thanks to his excellent expertise and wealth of experience in growth capital and pre-IPO finance, he has supported Marinomed AG every step of the way during an important phase in its development. Marinomed is now in a solid position for future growth owing also to his invaluable input."

About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company with headquarters in Vienna and has been listed in the Prime Market of the Vienna Stock Exchange. The company focuses on the development of innovative products based on patent-protected technology platforms. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as eyes, nose, lung or gastrointestinal tract. The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract and can reduce the risk of an infection with SARS-CoV-2. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 30 countries worldwide. Further information is available http://marinomed.com.

For further inquiries contact:

Dr. Eva Prieschl-Grassauer
Chief Scientific Officer, Marinomed
Hovengasse 25, 2100 Korneuburg, Österreich
T +43 2262 90300
E-Mail: eva.prieschl@marinomed.com
http://www.marinomed.com
Roland Mayrl
Managing Partner, Metrum Communications
Bauernmarkt 10/19, 1010 Wien, Österreich
T +43 (0) 1 504 69 87 331
E-Mail: r.mayrl@metrum.at
http://www.metrum.at

Disclaimer
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.

(end)

emitter: Marinomed Biotech AG
address: Hovengasse 25, 2100 Korneuburg
country: Austria
contact person: Dr. Eva Prieschl-Grassauer
phone: +43 2262 90300
e-mail: eva.prieschl@marinomed.com
website: www.marinomed.com

ISIN(s): ATMARINOMED6 (share)
stock exchanges: official trade in Vienna

[ source: http://www.pressetext.com/news/20201030009 ]

Related Links: Marinomed Biotech AG
Author: